Enterocutaneous fistula in severely active Crohn’s disease: preoperative anti-TNF alpha treatment to limit bowel resection—report of a case
- 52 Downloads
Strategies for limiting the extent of bowel resection in cases of enterocutaneous or interenteric fistulas in severely active Crohn’s disease are urgently necessary. Anti-inflammatory therapy with tumor necrosis factor alpha (anti-TNF alpha) inhibitors has positive impact on fistulizing Crohn’s disease. We describe a case of a 32-year-old male suffering from enterocutaneous fistula in severely active Crohn’s disease.
The patient’s clinical course and data of therapy monitoring before bowel resection were reviewed and compared to the pretherapeutic findings. In addition, the reports of surgery and histopathological workup were evaluated and a clinical follow-up was performed. The literature on anti-TNF alpha treatment in fistulizing Crohn’s disease was surveyed.
A 32-year-old male with an 8-year history of Crohn’s disease and condition after previous ileocecal and sigmoid resection at the age of 28 presented with increasing pain in the middle-right abdomen. Laboratory and radiologic assessment detected elevated C-reactive protein and presence of a conglomerate of inflammatory thickened and narrowed small intestine involving the neoterminal ileum and enteroenteric fistulas. Ileocolonoscopy showed a stenosing inflammation of the neoterminal ileum. After initial anti-infective therapy, as a result of an interdisciplinary decision, preoperative anti-TNF alpha treatment was performed to achieve limited bowel resection. After declining of inflammation, limited bowel resection was carried out successfully.
Preoperative therapy with anti-TNF alpha might potentially reduce inflammation to subsequently limit the extent of bowel resection in selected cases of enterocutaneous or interenteric fistulas in severely active Crohn’s disease. We describe an impressive case in which such therapeutic approach was carried out.
KeywordsSurgery in Crohn’s disease Inflammatory bowel disease IBD Enterocutaneous fistula Anti-TNF therapy
Compliance with ethical standards
Conflict of interest
Thomas Klag received speaker’s honorary from Abbvie. Jan Wehkamp received speaker’s honorary from Abbvie, MSD, Biogen, and Hexal. All remaining authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
The patient’s written consent was obtained for publication of this case report.
- 1.Frolkis AD, Dykeman J, Negron ME, Debruyn J, Jette N, Fiest KM, Frolkis T, Barkema HW, Rioux KP, Panaccione R, Ghosh S, Wiebe S, Kaplan GG (2013) Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 145:996–1006. https://doi.org/10.1053/j.gastro.2013.07.041 CrossRefGoogle Scholar
- 2.Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF (2005) Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19(Suppl A):5A–36ACrossRefGoogle Scholar
- 3.Memon AS, Siddiqui FG (2004) Causes and management of postoperative enterocutaneous fistulas. J Coll Physicians Surg Pak 14:25–28 11.2004/JCPSP.2528Google Scholar
- 7.Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885. https://doi.org/10.1056/NEJMoa030815 CrossRefGoogle Scholar
- 11.Ibanez-Samaniego L, Diaz-Fontenla F, Miranda-Bautista J, Acosta C, Barcelo I, Flores V, Echenagusia M, Camunez F, Diaz-Redondo A, Marin-Jimenez I, Menchen L (2015) Safety and efficacy of anti-TNF alpha treatment in Crohn’s disease patients with abdominal abscesses. Hepatogastroenterology 62:647–652Google Scholar
- 12.Brouquet A, Maggiori L, Zerbib P, Lefevre JH, Denost Q, Germain A, Cotte E, Beyer-Berjot L, Munoz-Bongrand N, Desfourneaux V, Rahili A, Duffas JP, Pautrat K, Denet C, Bridoux V, Meurette G, Faucheron JL, Loriau J, Guillon F, Vicaut E, Benoist S, Panis Y, group Gc (2018) Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort. Ann Surg 267:221–228. https://doi.org/10.1097/SLA.0000000000002017 CrossRefGoogle Scholar
- 13.Fumery M, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B, Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C, Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M, investigators Rsg (2017) Postoperative complications after ileocecal resection in Crohn’s disease: a prospective study from the REMIND Group. Am J Gastroenterol 112:337–345. https://doi.org/10.1038/ajg.2016.541 CrossRefGoogle Scholar